Faculty: Chemistry

Offer details

TECHNICAL OFFER
no. 23/1/2018
SECTOR
anticancer therapies
AUTHORS
Prof. Janusz Rak (WCh UG)
PhD Lidia Chomicz-Mańka (WCh UG)
PhD Marta Sosnowska (WCh UG)
PhD Samanta Makurat (WCh UG)
FACULTY
Chemistry
IP PROTECTION
The invention is the subject of patent protection: Pat.234558, UPRP EP3351535, EPO

COMMERCIALIZATION

Spin off
, Licence
, Sale of property rights
, Partnership for further research and commercialisation
TECHNOLOGY READINESS LEVEL
TRL 4
Technology validated in laboratory conditions.

Uracil derivative with radiosensitizing properties

Pochodna uracylu o właściwościach radiosensybilizujących

Radiotherapy is one of the most common therapeutic methods employed for human cancer treatment. This method uses ionizing radiation, which mainly acts indirectly via the radiolysis products of water damaging cellular DNA. Commonly used radiotherapy causes many side effects. Two  classes  of  radiosensitizing agents are distinguished: hypoxic cell sensitizers, which rely on hypoxia occurring only in cancer cells, and pyrimidine  analogues  that  could  be incorporated into DNA due to their structural similarity to native nucleosides.

The method allowing to increase
the effectiveness of radiotherapy is the use of the respective derivatives of nucleic bases radiosensitizers, operating in a low oxygen environment, that are incorporated into cellular DNA during its biosynthesis.

Technology offer

Get in touch